- Home
- CUE vs NTRB Comparison
CUE vs NTRB Comparison
Compare CUE & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- NTRB
- Stock Information
- Founded
- CUE 2014
- NTRB 2016
- Country
- CUE United States
- NTRB United States
- Employees
- CUE N/A
- NTRB N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- CUE Health Care
- NTRB Health Care
- Exchange
- CUE Nasdaq
- NTRB Nasdaq
- Market Cap
- CUE 61.1M
- NTRB 71.7M
- IPO Year
- CUE 2018
- NTRB N/A
- Fundamental
- Price
- CUE $0.56
- NTRB $5.29
- Analyst Decision
- CUE Strong Buy
- NTRB Buy
- Analyst Count
- CUE 2
- NTRB 1
- Target Price
- CUE $3.00
- NTRB $13.00
- AVG Volume (30 Days)
- CUE 394.8K
- NTRB 40.3K
- Earning Date
- CUE 11-12-2025
- NTRB 12-03-2025
- Dividend Yield
- CUE N/A
- NTRB N/A
- EPS Growth
- CUE N/A
- NTRB N/A
- EPS
- CUE N/A
- NTRB N/A
- Revenue
- CUE $7,100,000.00
- NTRB $2,578,059.00
- Revenue This Year
- CUE N/A
- NTRB $560.75
- Revenue Next Year
- CUE N/A
- NTRB $588.39
- P/E Ratio
- CUE N/A
- NTRB N/A
- Revenue Growth
- CUE N/A
- NTRB 42.92
- 52 Week Low
- CUE $0.54
- NTRB $3.72
- 52 Week High
- CUE $1.75
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- CUE 28.56
- NTRB 29.43
- Support Level
- CUE $0.57
- NTRB $5.07
- Resistance Level
- CUE $0.62
- NTRB $6.39
- Average True Range (ATR)
- CUE 0.08
- NTRB 0.36
- MACD
- CUE -0.01
- NTRB -0.09
- Stochastic Oscillator
- CUE 0.53
- NTRB 0.62
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.